|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0300 - 0.0330|
|52 Week Range||0.0200 - 0.1400|
|Beta (5Y Monthly)||0.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 13, 2020 - Aug. 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LAS VEGAS, NV / ACCESSWIRE / July 20, 2020 / GB Sciences, Inc.
LAS VEGAS, NV / ACCESSWIRE / May 4, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced today that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,653,640 entitled "Cannabinoid-Containing ...
LAS VEGAS / ACCESSWIRE / April 6, 2020 / GB Sciences, Inc. (GBLX), is pleased to announce that the company's Canadian entity, GBS Global Biopharma, Inc. (GBS), signed an Amendment to their Agreement with the National Research Council of Canada (NRC). The NRC has demonstrated that the company's PD formulations were able to reduce behavioral changes associated with the loss of dopamine-producing neurons, which underlies the pathology of Parkinson's disease in the animal model.